MONTANOVA CAPITAL, LLC (Cowen Aaron) sold $80.4M of MANE (indirect holdings)

MONTANOVA CAPITAL, LLC sold 750,000 indirectly-held shares of Veradermics, Inc (MANE) at $107.25 ($80.44M total) across 2 trades on 2026-08-19. Filed jointly with Cowen Aaron, Averill Master Fund, Ltd. (Director) and Averill Madison Master Fund, Ltd. (Director).

Original reporting
SEC EDGAR · MONTANOVA CAPITAL, LLC, Cowen Aaron, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.
Published Aug 21, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Bearish
high confidence
Mentioned
$MANE
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANEBearishMed
01

Why it matters

The $80.4M sale reduces insider ownership, potentially influencing investor sentiment and short-term price action.

02

Market read

Newly disclosed insider sale of significant size; may prompt traders to reassess position in MANE.

03

What to watch

Sale was executed via open market, not a block trade, possibly minimizing market impact.

Relevance 8/10Novelty 8/10Timing: filed Aug 21, 2026

Background

Form 4 filings disclose insider transactions; director sales are closely watched for signals.

Company-level read

Ticker impact

$MANEBearishHigh confidence
Context

Director Montanova Capital sold 750,000 shares for $80.4M, reducing its stake to 461,033 shares.

Expected impact

Potential short-term downside pressure.

Evidence & confidence

Large $80M sale by a director is material and newly disclosed via Form 4.

Market effects

May affect perception of the biotech/healthcare sector if insider sells are viewed as a red flag.

Limited to US markets where MANE trades.

Low, primarily relevant to investors in MANE.

Counterpoint

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Veradermics, Inc.

    Issuer of the shares sold.

  • Montanova Capital, LLC

    Director and reporting entity.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.